)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Zai Lab
Zai Lab (ZLAB) investor relations material
Zai Lab Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Q3 2026 revenue was $108.2M, down 7% YoY and up 1.8% QoQ; net loss widened to $46.1M from $36.0M.
Three pivotal zoci studies are targeted by year-end 2026, with two registrational readouts and a potential first U.S. BLA submission in 2027.
Commercial trends were mixed, while management targeted a return to meaningful revenue growth in 2027 as patient access expands.
Financial highlights
Q3 total revenue was $108.2M versus $116.1M YoY; net product revenue was $107.6M versus $115.4M, down 7% reported and up 29% at CER.
Q3 GAAP operating loss was $63.0M versus $48.8M; adjusted operating loss was $47.6M. Net loss was $46.1M versus $36.0M YoY.
Q3 R&D expense was $49.8M versus $47.9M YoY; SG&A was $70.1M in both periods.
Nine-month revenue was $314.1M versus $332.6M; net loss was $148.0M versus $125.1M YoY.
Outlook and guidance
Three registrational zoci studies across SCLC and neuroendocrine carcinomas are targeted by year-end 2026; two registrational readouts and a potential U.S. BLA submission are anticipated in 2027.
A global Phase 3 zoci plus PD-L1 study in first-line ES-SCLC is planned by year-end 2026; DLLEVATE interim analysis is expected in H2 2027.
Zoci 2L+ epNEC topline data are expected in H1 2027 and could support a U.S. accelerated approval submission; a U.S. launch could follow as early as 2028.
ZL-1503 atopic dermatitis patient data and ZL-6201 dose-escalation topline results are expected in H1 2027; ZL-1503 Phase 2 initiation is planned for 2027.
Meaningful revenue growth is targeted for 2027, supported by expanded patient access, priority-brand demand and potential NRDL-driven volume growth.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Zai Lab
- Zoci-atezolizumab showed an 81.8% ORR, supporting planned Phase 3 testing in 1L ES-SCLC.ZLAB
Investor update - Q2 2026 revenue reached $106.3M, with 11% sequential growth and robust cash reserves.ZLABQ2 2026
- ZL-1310 demonstrates strong efficacy in small cell lung cancer, with pivotal trials and new assets advancing.ZLABCiti's 2025 Virtual Oncology Leadership Summit
- ZL1310 demonstrates strong efficacy and safety in small cell lung cancer, advancing to phase III trials.ZLABAmerican Society of Clinical Oncology Annual Meeting 2025
- Strong pipeline progress and commercialization plans position the company for major growth in China.ZLABMorgan Stanley 23rd Annual Global Healthcare Conference
- All fourteen proposals, including director reelections and share mandates, were approved.ZLABAGM 2026
- Q1 2026 revenue fell 6% YoY to $99.6M; pipeline and launches support future growth.ZLABQ1 2026
- Profitable China operations and rapid global pipeline progress drive growth and innovation.ZLAB44th Annual J.P. Morgan Healthcare Conference
- Q3 2024 revenue up 47% to $101.8M, net loss narrowed to $41.7M, with strong product growth.ZLABQ3 2024
Next Zai Lab earnings date
Study update13 Nov, 2026
Zai Lab
Next Zai Lab earnings date
Study update13 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Zai Lab Limited is a biopharmaceutical company that focuses on developing and commercializing therapies for oncology, autoimmune disorders, infectious diseases, and neurological conditions. The company operates at the intersection of global research and localized healthcare needs, with a strong presence in China and the United States. Zai Lab has a broad portfolio that includes both licensed products and proprietary research-driven candidates, targeting areas of significant unmet medical need. The company is headquartered in Shanghai, China, and its shares are on both the Nasdaq and the Hong Kong Stock Exchange.